Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Sponsor: Wugen, Inc.
Summary
The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response
Official title: A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex)
Key Details
Gender
All
Age Range
1 Year - Any
Study Type
INTERVENTIONAL
Enrollment
125
Start Date
2025-01-31
Completion Date
2028-12-30
Last Updated
2026-01-05
Healthy Volunteers
No
Interventions
WU-CART-007
A single IV infusion of WU-CART-007
Locations (10)
City of Hope
Duarte, California, United States
Children's Hospital Los Angeles
Los Angeles, California, United States
H. Lee Moffitt Cancer Center and Research Institute Hospital
Tampa, Florida, United States
Washington University Saint Louis
St Louis, Missouri, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center
Houston, Texas, United States
Seattle Children's Hospital
Seattle, Washington, United States
Peter Mac Callum Cancer Institute
Melbourne, Victoria, Australia
Royal Children's Melbourne
Melbourne, Victoria, Australia